Evidence map›Paper›PMID 41353404›Full record

ArticleNature communications2025

A next-generation dual guide CRISPR system for genetic interaction library screening.

Thomas Burgold, Emre Karakoc, Emanuel Gonçalves, Inigo Barrio-Hernandez, Lisa Dwane, Romina Silva, Emily Souster, Mamta Sharma, Alexandra Beck, Gene Ching Chiek Koh and 3 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Thomas BurgoldWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK.ORCID http://orcid.org/0009-0006-8324-8934
Emre KarakocWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK.
Emanuel GonçalvesWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK.ORCID http://orcid.org/0000-0002-9967-5205
Inigo Barrio-HernandezWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK.
Lisa DwaneWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK.
Romina SilvaWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK.ORCID http://orcid.org/0000-0001-5429-0152
Emily SousterWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK.
Mamta SharmaWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK.
Alexandra BeckWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK.
Gene Ching Chiek KohWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK.ORCID http://orcid.org/0000-0002-3840-4954
Lykourgos-Panagiotis ZalmasOpenTargets, Wellcome Genome Campus, Hinxton, Cambridge, UK.
Mathew J GarnettWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK.ORCID http://orcid.org/0000-0002-2618-4237
Andrew R BassettWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK. ab42@sanger.ac.uk.ORCID http://orcid.org/0000-0003-1632-9137

Funding

Wellcome TrustWellcome Trust (Wellcome) 220540/Z/20/A
6 · The paper itself

Abstract

Pairwise perturbation of gene function using the CRISPR/Cas9 system has potential in screening for genetic interactions and synthetic lethal gene pairs to identify combination therapies for cancer. However, existing dual guide expression systems are cumbersome to clone, often result in a large proportion of undesired guide pairs and have an imbalance of guide expression from the two positions. Here, we demonstrate a next-generation system for dual guide delivery based around a tRNA spacer that allows a single-step cloning strategy, as little as 2% of undesired guide pairs, and highly balanced expression of the two guides. This system allows efficient library-scale screening for hundreds of thousands of genetic interactions using the well-understood Streptococcus pyogenes Cas9 (SpCas9) system. We use this to screen a 100,136 guide pair library in colorectal cancer cells and successfully identify synthetic lethal genetic interactions between paralogs or other known interacting genes, establishing our method for performing efficient large-scale genetic interaction screens. This system is versatile and could be used with most guide RNA vector systems, and for other uses of paired guide delivery, such as improving single gene knockout efficiency or improving guide detection in single cell or optical CRISPR screens.

Indexed as

CRISPR-Cas SystemsGene LibraryRNA, Guide, CRISPR-Cas SystemsCell Line, TumorClustered Regularly Interspaced Short Palindromic RepeatsColorectal NeoplasmsCRISPR-Associated Protein 9HumansRNA, TransferStreptococcus pyogenesCRISPR-Associated Protein 9RNA, Guide, CRISPR-Cas SystemsRNA, Transfer

Identifiers

PMID41353404
PMCPMC12808759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.